Advertisement

FDA Approves Ceritinib for Metastatic Lung Cancer — Physician’s First Watch

Medical News |
May 1, 2014

FDA Approves Ceritinib for Metastatic Lung Cancer

By Kristin J. Kelley

The anaplastic lymphoma kinase (ALK) inhibitor ceritinib (marketed as Zykadia) has been granted accelerated approval to treat metastatic non–small-cell lung cancer (NSCLC) in patients with a mutation of the ALK gene who have been previously treated with crizotinib.

Only 2% to 7% of patients with NSCLC have ALK-positive tumors but, writes Anne Tsao in NEJM Journal Watch Oncology and Hematology, resistance to crizotinib is a significant problem in this population.

Approval was based on a trial in which some 160 patients with metastatic ALK-positive NSCLC were treated with ceritinib. Tumors shrunk in half of these patients — an effect that lasted, on average, about 7 months.

A Novartis official says that pricing information for the drug isn't available yet. However, PMLiVE reports that it will launch at $13,500/month.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement